Becton, Dickinson and Company Names Francesca Demartino as Senior Vice President of Investor Relations, Effective Effective November 29, 2021
November 24, 2021 at 06:50 am
Share
Becton, Dickinson and Company announced Francesca DeMartino has been named senior vice president of investor relations for the company, effective November 29, 2021. In this role, DeMartino will lead all aspects of communicating progress of the BD2025 strategy to investors and the financial community, including the company's initiatives that drive shareholder value. DeMartino will report to Chris DelOrefice, executive vice president and chief financial officer for BD. She succeeds Kristen Stewart who has been named senior vice president of enterprise strategy and insights for BD. DeMartino has more than 20 years of combined experience in investor relations, communications and corporate finance, with her most recent position as vice president of investor relations at Medtronic. Prior to joining Medtronic, DeMartino held positions of increasing responsibility at Johnson & Johnson, OMRIX Biopharmaceuticals, Macrocure Ltd, GCI Group and The Ruth Group.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
BECTON, DICKINSON AND COMPANY 
